The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...

A significant minority of patients with brain metastases may avoid radiotherapy, but they need to be carefully selected.

The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.

Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application ...

The sBLA is supported by results from the phase IIIDESTINY-Breast06 trial (NCT04494425), which showed that patients with HER2 ...

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Tuesday said their cancer drug Enhertu received a priority review by the Food & Drug Administration in the US for some forms of breast ...

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...

Novellia, Inc ., an AI-enabled personal health data company dedicated to bridging the gap between real-world patient experience and precision healthcare, announced initial results from its ...

That comes amid mixed results for its experimental drug with partner Daiichi Sankyo Co., and analyst concerns about the ...

In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.